15-SORRENTO-Therapeutics-Logo-FINAL.png
SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
April 02, 2020 12:33 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren,...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program
March 25, 2020 10:00 ET | Sorrento Therapeutics, Inc.
STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virusThe I-Cell vaccine is...
15-SORRENTO-Therapeutics-Logo-FINAL.png
SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19
March 23, 2020 09:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and BOSTON, March 23, 2020 (GLOBE NEWSWIRE) -- In response to the government call for rapidly deployable countermeasures, Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) and...
15-SORRENTO-Therapeutics-Logo-FINAL.png
SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
March 20, 2020 07:00 ET | Sorrento Therapeutics, Inc.
COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
February 27, 2020 06:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will present at the 9th Annual LEERINK...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
February 21, 2020 09:15 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that it will present at LEERINK Partners 9th Annual Global Healthcare Conference...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection
January 29, 2020 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO and WARREN, N.J., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it has initated a clinical and manufacturing collaboration with...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Board Rejects Latest Acquisition Proposal
January 27, 2020 07:00 ET | Sorrento Therapeutics, Inc.
The latest non-binding proposal received on January 9, 2020 from a private equity fund to acquire a majority or all of the issued and outstanding shares of the company for “up to $7.00” per share...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences
January 27, 2020 07:00 ET | Sorrento Therapeutics, Inc.
Phase 1b/2 OA Knee Pain study completed enrollment of 93 patients, with no dose limiting toxicities observed and significant efficacy signal confirmed in expansion cohorts. The program is expected to...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors
December 16, 2019 07:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr....